The Indian Pharmaceutical Alliance disputed U.S. allegations that India's patent law is discriminatory. A number of U.S. drugmakers have significantly increased their market capitalization and revenues since the implementation of Indian patent law changes in 2005, IPA said. "We are not aware of any provision in India's patent law that discriminates against U.S. companies," IPA Secretary General D.G. Shah said.

Related Summaries